{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:09:16Z","timestamp":1788822556561,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2023IP0112-1"],"award-info":[{"award-number":["2023IP0112-1"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jbspin.2023.105668","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T23:01:30Z","timestamp":1701212490000},"page":"105668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study"],"prefix":"10.1016","volume":"91","author":[{"given":"Young-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-6492","authenticated-orcid":false,"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-3124","authenticated-orcid":false,"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2023.105668_bib0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jbspin.2023.105668_bib0240","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2023.105668_bib0245","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.2005.049023","article-title":"Gout, diuretics and the kidney","volume":"65","author":"Pascual","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0250","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2215\/CJN.06790616","article-title":"The 3-year incidence of gout in elderly patients with CKD","volume":"12","author":"Tan","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2023.105668_bib0255","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1002\/art.38171","article-title":"Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study","volume":"65","author":"Krishnan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105668_bib0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jbspin.2023.105668_bib0265","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105668_bib0270","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0275","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2023.105668_bib0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0285","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-018-1559-2","article-title":"Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort","volume":"20","author":"Ranieri","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2023.105668_bib0290","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/pds.5127","article-title":"Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: a retrospective observational study of Japanese health insurance claims data","volume":"30","author":"Koto","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jbspin.2023.105668_bib0295","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2169\/internalmedicine.1899-18","article-title":"Achievement of target serum uric acid levels and factors associated with therapeutic failure among Japanese men treated for hyperuricemia\/gout","volume":"58","author":"Katayama","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/CEOR.S139939","article-title":"Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat","volume":"9","author":"Sheer","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jbspin.2023.105668_bib0305","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jbspin.2017.03.013","article-title":"Persistent clinical inertia in gout in 2014: an observational French longitudinal patient database study","volume":"85","author":"Maravic","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105668_bib0310","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40744-017-0091-1","article-title":"Improvement in diagnosis and treat-to-target management of hyperuricemia in gout: results from the GEMA-2 transversal study on practice","volume":"5","author":"Perez Ruiz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2023.105668_bib0315","first-page":"27","article-title":"Gout: state of the art after a decade of developments","volume":"58","author":"Pascart","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2023.105668_bib0320","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-018-1755-0","article-title":"How much allopurinol does it take to get to target urate? comparison of actual dose with creatinine clearance-based dose","volume":"20","author":"Stamp","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2023.105668_bib0325","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcp.12799","article-title":"Predicting allopurinol response in patients with gout","volume":"81","author":"Wright","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2023.105668_bib0330","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0335","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105668_bib0340","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105668_bib0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0350","doi-asserted-by":"crossref","first-page":"152073","DOI":"10.1016\/j.semarthrit.2022.152073","article-title":"Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: a meta-analysis of observational studies","volume":"56","author":"Jeong","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2023.105668_bib0355","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3904\/kjim.2018.423","article-title":"Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0360","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4258\/hir.2014.20.2.109","article-title":"Characteristics desired in clinical data warehouse for biomedical research","volume":"20","author":"Shin","year":"2014","journal-title":"Healthc Inform Res"},{"key":"10.1016\/j.jbspin.2023.105668_bib0365","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13075-017-1390-1","article-title":"Performance of gout definitions for genetic epidemiological studies: analysis of UK Biobank","volume":"19","author":"Cadzow","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2023.105668_bib0370","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/annrheumdis-2020-219796","article-title":"Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank","volume":"80","author":"Sandoval-Plata","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0375","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4078\/jrd.2019.26.2.118","article-title":"Comparison of efficacy and safety of febuxostat in gout patients with chronic kidney disease stage 3 and stage 4\/5","volume":"26","author":"Ahn","year":"2019","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0380","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jbspin.2016.09.020","article-title":"Efficacy and safety of febuxostat in 73 gouty patients with stage 4\/5 chronic kidney disease: a retrospective study of 10 centers","volume":"84","author":"Juge","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2023.105668_bib0385","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1517\/17425255.2014.904285","article-title":"Febuxostat: drug review and update","volume":"10","author":"Grewal","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jbspin.2023.105668_bib0390","doi-asserted-by":"crossref","first-page":"33082","DOI":"10.1038\/srep33082","article-title":"Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jbspin.2023.105668_bib0395","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/imj.14776","article-title":"Efficacy and tolerability of febuxostat in gout patients on dialysis","volume":"51","author":"Choi","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.jbspin.2023.105668_bib0400","first-page":"1859","article-title":"Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis","volume":"16","author":"Liu","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0405","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40262-016-0466-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of febuxostat","volume":"56","author":"Kamel","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jbspin.2023.105668_bib0410","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jcph.1023","article-title":"Population pharmacodynamic analysis of uric acid-lowering effects of febuxostat based on electronic medical records in two hospitals","volume":"58","author":"Muraki","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2023.105668_bib0415","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","article-title":"Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting","volume":"10","author":"Riedel","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2023.105668_bib0420","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4078\/jrd.2019.26.2.118","article-title":"Comparison of efficacy and safety of febuxostat in gout patients with chronic kidney disease stage 3 and stage 4\/5","volume":"26","author":"Ahn","year":"2019","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0425","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","article-title":"Association of chronic kidney disease with allopurinol use in gout treatment","volume":"178","author":"Vargas-Santos","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0430","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","article-title":"Uric acid and the risks of kidney failure and death in individuals with CKD","volume":"71","author":"Srivastava","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0435","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","article-title":"Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level","volume":"47","author":"Siu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jbspin.2023.105668_bib0445","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0450","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2023.105668_bib0455","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/acr.22067","article-title":"Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2023.105668_bib0460","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.3390\/jcm11195742","article-title":"Simple application and adherence to gout guidelines enables disease control: an observational study in French referral centres","volume":"11","author":"Jauffret","year":"2022","journal-title":"J Clin Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X23001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:31:57Z","timestamp":1761150717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X23001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1297319X23001471"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105668","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2023.105668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105668"}}